BIMI Holdings Inc.: Nasdaq/NYSE listing notice — BIMI receives Nasdaq deficiency notices for late 10-K and bid price below $1

BIMI Holdings Inc.

Received Nasdaq notice on Apr 18, 2023 for failing to file FY2022 10-K by deadline per Listing Rule 5250(c)(1).
Received separate bid price deficiency notice on Apr 19, 2023; closing bid below $1.00 for 30 consecutive days.
Company has 60 days to submit compliance plan for 10-K; possible 180-day extension if plan accepted.
For bid price, compliance period runs until Oct 16, 2023; can be cured by 10 consecutive days at $1.00+.
Shares continue trading on Nasdaq Capital Market under symbol BIMI while company evaluates options.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

BIMI Holdings Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

April 19, 2023, the Company received a deficiency letter (the “Nasdaq Bid Price Deficiency Letter”) from Nasdaq notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). The Nasdaq Bid Price Deficiency Letter has no immediate effect on the listing of the Company’s common stock, and its common stock will continue to trade on The Nasdaq Capital Market under the symbol “BIMI” at this tim

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

BIMI Holdings Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: late filing
Rules: 5250(c)(1)

Exact text from the filing

April 18, 2023, BIMI International Medical Inc. (the “Company”) received a notification letter (the “Nasdaq 10K Delinquency Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) stating that, because the Company has not yet filed its Annual Report on Form 10-K for the period ended December 31, 2022 (the “Form 10-K”), the Company is no longer in compliance with Nasdaq Listing Rule 5250(c)(1). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission. The Nasdaq 10K Delinquency Letter states that the

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001213900-23-031331

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.